Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M M Raemaekers

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Current Opinion in Oncology|October 15, 2005
Angiogenesis in malignant lymphomaAd Koster, John M M Raemaekers
Current Opinion in Oncology|September 22, 2006
Chemotherapy and radiotherapy in Hodgkin's lymphoma: joining in or splitting up?Richard W M van der Maazen, John M M Raemaekers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Radiotherapy in advanced-stage Hodgkin's lymphomaJohn M M Raemaekers, Berthe M P Aleman, Michel Henry-Amar
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2013
Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphomaMarieke H Verhappen, Philip M P Poortmans, Esther Raaijmakers, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|May 29, 2004
Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphoma A meeting report of the Second International Lunenburg Lymphoma WorkshopMarie José Kersten, Daphne de Jong Dd, John M M Raemaekers, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 19, 2015
[The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment]Nicky Dekker, Mars B van 't Veer, Berthe M P Aleman, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphomaErnst J Postema, Cathelijne Frielink, Wim J G Oyen, et al.
Haematologica|February 14, 2007
The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphomaAd Koster, Hedwig A Tromp, John M M Raemaekers, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|January 26, 2008
Protein profiling of B-cell lymphomas using tissue biopsies: A potential tool for small samples in pathologyCorine Jansen, Konnie M Hebeda, Marianne Linkels, et al.
British Journal of Haematology|December 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trialsValeria Fiaccadori, Anouk Neven, Catherine Fortpied, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Current Opinion in Oncology|October 15, 2005
Angiogenesis in malignant lymphomaAd Koster, John M M Raemaekers
Current Opinion in Oncology|September 22, 2006
Chemotherapy and radiotherapy in Hodgkin's lymphoma: joining in or splitting up?Richard W M van der Maazen, John M M Raemaekers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Radiotherapy in advanced-stage Hodgkin's lymphomaJohn M M Raemaekers, Berthe M P Aleman, Michel Henry-Amar
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2013
Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphomaMarieke H Verhappen, Philip M P Poortmans, Esther Raaijmakers, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|May 29, 2004
Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphoma A meeting report of the Second International Lunenburg Lymphoma WorkshopMarie José Kersten, Daphne de Jong Dd, John M M Raemaekers, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 19, 2015
[The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment]Nicky Dekker, Mars B van 't Veer, Berthe M P Aleman, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphomaErnst J Postema, Cathelijne Frielink, Wim J G Oyen, et al.
Haematologica|February 14, 2007
The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphomaAd Koster, Hedwig A Tromp, John M M Raemaekers, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|January 26, 2008
Protein profiling of B-cell lymphomas using tissue biopsies: A potential tool for small samples in pathologyCorine Jansen, Konnie M Hebeda, Marianne Linkels, et al.
British Journal of Haematology|December 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trialsValeria Fiaccadori, Anouk Neven, Catherine Fortpied, et al.
Pageof 4